Sign in

    Scott McAuley

    Research Analyst at Paradigm Capital

    Scott McAuley, PhD, is the Head of Research and Equity Research Analyst for Healthcare and Biotechnology at Paradigm Capital, where he oversees the research team and specializes in life sciences coverage. He is recognized for his research on companies in the healthcare and biotechnology sectors, with a focus on providing differentiated analysis though specific company names and quantitative performance metrics are not publicly disclosed. McAuley joined Paradigm Capital several years ago after a career in academic research, including a PhD in Biochemistry from the University of Toronto, experience as a communications coordinator, and co-founding a science-focused startup. He holds advanced academic credentials and leverages this background in both scientific research and industry analysis to guide institutional investment decisions.

    Scott McAuley's questions to Profound Medical (PROF) leadership

    Scott McAuley's questions to Profound Medical (PROF) leadership • Q1 2025

    Question

    Scott McAuley from Paradigm Capital asked for details on the Q1 capital revenue, specifically if it represented new installations or conversions of existing sites. He also inquired about the timing and economic model of the TULSA-PLUS program, including any potential benefits from the Siemens MRI partnership.

    Answer

    CFO Rashed Dewan clarified that the Q1 capital revenue was from two new sites and one conversion from an existing site. CEO Arun Menawat stated that TULSA-PLUS compatibility should be ready by the end of Q3, with deals expected around that time. He emphasized the focus is on driving TULSA procedures, regardless of how the MRI is sourced. CCO Thomas Tamberrino added that TULSA-PLUS is a comprehensive "soup to nuts" program solution, not just an MRI offering, customized to each site's needs.

    Ask Fintool Equity Research AI

    Scott McAuley's questions to Profound Medical (PROF) leadership • Q1 2025

    Question

    Scott McAuley from Paradigm Capital requested details on the Q1 capital revenue, asking if it stemmed from new installations or conversions. He also inquired about the availability timeline for the TULSA-PLUS program and the economic structure of the Siemens partnership.

    Answer

    CFO Rashed Dewan clarified that the Q1 capital revenue was generated from two new site installations and one conversion of an existing site. CEO Arun Menawat projected that TULSA-PLUS compatibility and initial deals would be ready by the end of Q3. He explained the goal is to drive TULSA procedure revenue, remaining flexible on how the MRI hardware is sourced. CCO Thomas Tamberrino added that TULSA-PLUS is a comprehensive, customizable program that extends beyond just the magnet to provide a complete 'soup to nuts' solution for launching a TULSA program.

    Ask Fintool Equity Research AI

    Scott McAuley's questions to Profound Medical (PROF) leadership • Q2 2024

    Question

    Scott McAuley of Paradigm Capital sought clarification on the source of the reported capital equipment revenue, asking if it originated from North America or international markets like Europe.

    Answer

    CEO Arun Menawat and CFO Rashed Dewan confirmed that the capital sale was in North America, as detailed in the financial statements' segment report.

    Ask Fintool Equity Research AI